BIONDVAX PHARMA/S (NASDAQ:BVXV) – Research analysts at Zacks Investment Research issued their Q2 2019 EPS estimates for BIONDVAX PHARMA/S in a research note issued to investors on Wednesday, June 12th. Zacks Investment Research analyst D. Bautz anticipates that the company will post earnings of ($0.02) per share for the quarter. Zacks Investment Research also issued estimates for BIONDVAX PHARMA/S’s Q3 2019 earnings at ($0.03) EPS, Q4 2019 earnings at ($0.03) EPS and FY2021 earnings at ($0.07) EPS.
Separately, ValuEngine upgraded shares of BIONDVAX PHARMA/S from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd.
Shares of BIONDVAX PHARMA/S stock opened at $5.89 on Friday. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 2.95. BIONDVAX PHARMA/S has a 1 year low of $3.51 and a 1 year high of $7.26.
BIONDVAX PHARMA/S (NASDAQ:BVXV) last issued its earnings results on Tuesday, April 30th. The company reported ($1.81) earnings per share (EPS) for the quarter.
About BIONDVAX PHARMA/S
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.
Further Reading: What is total return in investing?
Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.